肥胖一直是公众所密切关注的重要议题,2023世界肥胖图谱(The World Obesity Atlas 2023)显示,如果我们不采取任何行动,那么到2035年,全球超重和肥胖人口将会超过40亿。随着肥胖人口增加以及在胰高血糖样肽-1(GLP-1)类减重药物上的突破,近期产业界减重疗法管线也大幅增长。IQVIA近期对当前全球减肥药物的研发管线进行了盘点。
The 2023 version of the World Obesity Map predicts that by 2035, over 4 billion people worldwide will be obese or overweight, accounting for 51% of the global population, while the world's largest obese country may have an overweight rate of over 67%. û收藏 转发 ...
showcasing new research in obesity treatment,highlights of the key results of the Chinese translation of the 2024 World Obesity Atlas released by the WOF, key findings from studies on obesity risk factors in China, the top ...
If the prevalence of obesity continues on its rising trend, almost half of the world’s adult population could be overweight or obese by 2030, imposing even greater personal, social, and economic costs. Effectively combating obesity around the world may
Sepsis is a significant contributor to both intensive care unit (ICU) admissions and mortality among patients in ICU, with a rising prevalence of obesity. There is a lack of extensive research on the correlation between TyGI and findings in patients with sepsis, especially in obese patients. ...
from the USD 6 billion market earlier this year.1 That’s based on World Obesity Atlas data that predicts over 50% of the world’s population will be ‘obese’ by 2035, from 38% in 2020, and predicated on around 15 million patients in the US alone regularly taking anti-obesity drugs....
DisordersCurrent View of Foot and AnkleDiagnosis and Management of Otitis MediaDietary Management in the Obesity TreatmentDiscovering the World of Rare DiseasesDiscovering the World of Rare Diseases: 2nd EditionDrug-Drug Interaction in PharmacologyEffects of Sport Activities on Physical and Mental Health ...
Despite varied treatment, mitigation, and prevention efforts, the global prevalence and severity of obesity continue to worsen. Here we propose a combined model of obesity, a unifying paradigm that links four general models: the energy balance model (EBM
Spatial atlas reveals insight into lung immunity Nature Genetics Research Briefing 06 Jan 2023 Sections Figures References Abstract Main Results Discussion Methods Data availability Code availability References Acknowledgements Author information Ethics declarations Peer review Additional information Extended data...
3.译文:自2023年伊始,减肥药Wegovy(及其同类产品Ozempic减肥药)的制造商诺和诺德的市值飙升了87%,至5600亿美元,成为欧洲市值最高的公司。 1.原文:Many are testing versionsthat are distinct enough from Wegovy and Zepboundthat patent protections will not apply,allowing them to come to marketwithin a few ...